title: Escitalopram in the treatment of generalized anxiety disorder.
abstract: The selective serotonin reuptake inhibitor escitalopram is the active enantiomer of citalopram and has proven efficacy in the treatment of major depression, panic disorder and social phobia. Accumulating data indicate that it is also efficacious in the treatment of patients with generalized anxiety disorder. This drug profile summarizes the current evidence-base for the treatment of generalized anxiety disorder, describes the findings of a series of randomized placebo-controlled and comparator-controlled trials of escitalopram, examines the strengths and weaknesses of current treatment approaches and considers potential new therapies for the treatment of this common, chronic and impairing anxiety disorder. In summary, escitalopram is effective and well tolerated in both the short- and long-term treatment of generalized anxiety disorder, and has advantages over benzodiazepines and the selective serotonin reuptake inhibitor paroxetine.
authors: Division of Clinical Neurosciences, University Department of Mental Health, RSH Hospital, Graham Road, Southampton, SO14 0YG, UK. dsb1@soton.ac.uk
authors: David S
authors: DS
authors: Baldwin
authors: Rajesh V
authors: RV
authors: Nair
mesh_terms: D001008:Anxiety Disorders / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D015283:Citalopram / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D006801:Humans
chemical_list: D015283:Citalopram